Table 2 Patient baseline characteristics
Characteristic | Tiotropium (n=238) | Placebo (n=219) |
|---|---|---|
Age, years | 61.2±8.2 | 62.3±8.6 |
Male, % | 69.7 | 67.1 |
Height, cm | 171.4±8.2 | 170.5±8.3 |
Weight, kg | 79.7±16.6 | 83.2±20.1 |
BMI, kg/m2 | 27.0±4.9 | 28.5±5.9 |
Current smoker, % | 61.7 | 57.0 |
Smoking history, pack-years | 44.0±22.4 | 43.9±34.9 |
Pre-bronchodilator | ||
FEV1, l | 1.75±0.44 | 1.70±0.44 |
FVC, l | 3.25±0.79 | 3.17±0.84 |
Post-bronchodilator | ||
FEV1, l | 1.95±0.44 | 1.90±0.43 |
FEV1, % predicted | 65.6±8.2 | 65.8±8.2 |
FVC, l | 3.53±0.80 | 3.41±0.87 |
FEV1/FVC | 0.6±0.1 | 0.6±0.1 |
WPAI | ||
Activity impairment due to health, % a | 28.0±22.3 | 25.4±21.4 |
Patients employed, % | 41 | 37 |
Impairment while working due to health, % b | 21.1±21.1 | 17.2±20.2 |
Median | GM (95% CI) | Median | GM (95% CI) | |
|---|---|---|---|---|
Activity c | ||||
Steps, number/day | 6,748.7 | 6,374.5 (5,889.2–6,899.9) | 6,901.8 | 6,433.3 (5,950.7–6,955.0) |
Time in moderate or higher (≥3 METs), min/day | 86.8 | 77.2 (67.9–87.7) | 73.8 | 68.6 (59.6–78.9) |
Time in age-appropriate moderate or higher activity, min/day | 24.7 | 20.62 (16.85–25.22) | 20.6 | 19.28 (15.77–23.57) |
